THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • September 18th, 2019 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 18th, 2019 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of December 18, 2017, by and among Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), the Key Holders (as defined below), each Holder (as defined below) listed on Schedule I hereto (each Key Holder and Holder, a “Stockholder” and collectively, the “Stockholders”) and each stockholder of the Company that becomes a party to this Agreement in accordance with Section 6.9 hereof (each, an “Additional Stockholder”). Capitalized terms used in this Agreement but not otherwise defined have the meanings set forth in Sections 1.1 and 1.2.
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 5th, 2018 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of December 18, 2017, by and among Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), the Key Holders (as defined below), each Holder (as defined below) listed on Schedule I hereto (each Key Holder and Holder, a “Stockholder” and collectively, the “Stockholders”) and each stockholder of the Company that becomes a party to this Agreement in accordance with Section 6.9 hereof (each, an “Additional Stockholder”). Capitalized terms used in this Agreement but not otherwise defined have the meanings set forth in Sections 1.1 and 1.2.
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • October 19th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 19th, 2018 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of December 18, 2017, by and among Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), the Key Holders (as defined below), each Holder (as defined below) listed on Schedule I hereto (each Key Holder and Holder, a “Stockholder” and collectively, the “Stockholders”) and each stockholder of the Company that becomes a party to this Agreement in accordance with Section 6.9 hereof (each, an “Additional Stockholder”). Capitalized terms used in this Agreement but not otherwise defined have the meanings set forth in Sections 1.1 and 1.2.